GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioxytran Inc (OTCPK:BIXT) » Definitions » Earnings per Share (Diluted)

Bioxytran (Bioxytran) Earnings per Share (Diluted) : $-0.04 (TTM As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Bioxytran Earnings per Share (Diluted)?

Bioxytran's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.04.

Bioxytran's EPS (Basic) for the three months ended in Mar. 2024 was $-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.04.

Bioxytran's EPS without NRI for the three months ended in Mar. 2024 was $-0.01. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.04.

During the past 5 years, the average EPS without NRI Growth Rate was -40.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was 51.50% per year.

During the past 13 years, Bioxytran's highest 3-Year average EPS without NRI Growth Rate was 92.20% per year. The lowest was -162.10% per year. And the median was 53.60% per year.


Bioxytran Earnings per Share (Diluted) Historical Data

The historical data trend for Bioxytran's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioxytran Earnings per Share (Diluted) Chart

Bioxytran Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 -0.03 -0.04 -0.02 -0.03

Bioxytran Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.01 -0.01 -0.01

Competitive Comparison of Bioxytran's Earnings per Share (Diluted)

For the Biotechnology subindustry, Bioxytran's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioxytran's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioxytran's PE Ratio distribution charts can be found below:

* The bar in red indicates where Bioxytran's PE Ratio falls into.



Bioxytran Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Bioxytran's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2023 is calculated as

Diluted Earnings Per Share (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-4.28-0)/134.225
=-0.03

Bioxytran's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2024 is calculated as

Diluted Earnings Per Share (Q: Mar. 2024 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-0.8-0)/162.808
=-0.00

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Bioxytran  (OTCPK:BIXT) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Bioxytran Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Bioxytran's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioxytran (Bioxytran) Business Description

Industry
Traded in Other Exchanges
N/A
Address
75 2nd Avenue, Suite 605, Needham, MA, USA, 02494
Bioxytran Inc is a biopharmaceutical company. The company is engaged in developing anti-necrosis drugs that treat a variety of medical conditions resulting from Ischemia. It is also focusing on the development and commercialization of treatments to prevent catastrophic brain damage resulting from hypoxic conditions following brain stroke. Its product candidate, BXT-25, is an anti-necrosis drug that carries oxygen to tissues when the flow of blood is blocked. Its other drug candidate BXT-252 is a resuscitative agent in a variety of wound healing applications.
Executives
Dale H Conaway director 189 WELLS AVE, NEWTON MA 02459
Alan M Hoberman director 6134 MECHANICSVILLE ROAD, PO BOX 56, MECHANICSVILLE PA 18934
Anders Utter director BIOXYTRAN, INC, 233 NEEDHAM ST., SUITE 300, NEWTON MA 02464
David Platt director, 10 percent owner, officer: CEO 12 APPLETON CIRCLE, NEWTON MA 02459
Hana Chen-walden director 7 RUE ARISTIDE MAILLOL, PARIS I0 75015
Michael Sheikh officer: Chief Communication Officer 1905 S AUDUBON CT, SPOKANE WA 99224
Binder Offer other: No longer 10% owner PASQUALE VIA SETTEMBRIMI 14A, SAN MARIANO 06073, CORCIANO PG ITALY L6 00000
Ola Soderquist 10 percent owner, officer: CFO 47 HAMMOND STREET, UNIT 2, WALTHAM MA 02451
Lawrence W. Bonafide director 78365 HWY 111, SUITE 287, LA QUINTA CA 92253
Nathan Marks director 78365 HWY 111, SUITE 287, LA QUINTA CA 92253
Dave Quincy Farber director, officer: President 78365 HWY 111, SUITE 287, LA QUINTA CA 92253
David Lee director 78365 HWY 111, SUITE 287, LA QUINTA CA 92253
Donita R. Kendig director, officer: Secretary/Treasurer 78365 HWY 11, SUITE 287, LA QUINTA CA 92253
Afcc, Llc 10 percent owner 1621 CENTRAL AVENUE, CHEYENNE WY 82001
Paul W Hai 10 percent owner 20443 TIMBERLINE, BEND OR 97701